Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/12/2007CA2284551C New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
06/12/2007CA2249410C Sigma-2 receptors as biomarkers of tumor cell proliferation
06/12/2007CA2248772C Novel peptides which inhibit complement activation
06/12/2007CA2246235C Colonic delivery of nicotine to treat inflammatory bowel disease
06/12/2007CA2238410C Novel indole-2,3-dione-3-oxime derivatives
06/12/2007CA2215834C Dna encoding human papillomavirus type 18
06/12/2007CA2198005C Pyrazolo[3,4-g]quinoxaline compounds which inhibit pdgf receptor protein tyrosine kinase
06/12/2007CA2184065C Inhibition of arterial smooth muscle cell proliferation
06/12/2007CA2173975C Recombinant adenoviral vector and methods of use
06/12/2007CA2173418C Benzonitriles and benzofluorides
06/12/2007CA2145585C N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells
06/12/2007CA2130828C Non-azo naphthalimide dyes and uses for same
06/12/2007CA1341530C Inhibitors of angiogenin
06/09/2007CA2529677A1 Method of modulating gene transcription
06/08/2007CA2570444A1 Absorbable stent comprising coating for controlling degradation and maintaining ph neutrality
06/08/2007CA2539874A1 Novel uses of scleraxis
06/07/2007WO2007065167A1 Use of high-dose oxazaphosphorine drugs for treating immune disorders
06/07/2007WO2007065100A1 Pyrrolotriazine kinase inhibitors
06/07/2007WO2007065093A2 Pyrrolidineanilines
06/07/2007WO2007065080A2 Control of apoptosis by controlling the propensity of ceramide channel formation
06/07/2007WO2007065032A2 Compounds and methods for inhibiting viral entry
06/07/2007WO2007065023A2 Processes for obtaining lignan extracts and compositions containing the lignan extracts
06/07/2007WO2007065010A2 Anti-angiogenesis compounds
06/07/2007WO2007065007A2 Treatment of viral infections
06/07/2007WO2007064968A2 Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
06/07/2007WO2007064954A2 Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
06/07/2007WO2007064945A2 Cancer therapies and pharmaceutical compositions used therein
06/07/2007WO2007064932A2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
06/07/2007WO2007064931A2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
06/07/2007WO2007064926A2 Compositions containing ansamycin
06/07/2007WO2007064914A2 5-(arylsulfonyl)-pyrazolopiperidines
06/07/2007WO2007064912A2 Mometasone compositions and methods of making and using the same
06/07/2007WO2007064891A1 Compositions and methods for inducing neuronal differentiation
06/07/2007WO2007064883A2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
06/07/2007WO2007064881A2 Implantable microbial cellulose materials for various medical applications
06/07/2007WO2007064872A2 Urea compounds useful in the treatment of cancer
06/07/2007WO2007064871A2 Diagnostic and treatment regimen for achieving body water homeostasis
06/07/2007WO2007064800A2 Methods to ameliorate and image angioplasty-induced vascular injury
06/07/2007WO2007064797A2 Inhibitors of c-met and uses thereof
06/07/2007WO2007064795A2 Purine derivatives and methods of use thereof
06/07/2007WO2007064762A2 Conjugates of amino acids and vitamin b3 for percutaneous delivery of vitamin b3
06/07/2007WO2007064755A2 Treatment of xerostomia with a sulfur-containing antioxidant
06/07/2007WO2007064753A2 Cancer treatment method
06/07/2007WO2007064749A1 Compounds for the treatment of inflammatory disorders and microbial diseases
06/07/2007WO2007064741A2 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
06/07/2007WO2007064738A1 Methods of reducing adverse events associated with pirfenidone therapy
06/07/2007WO2007064732A1 Compounds for the treatment of inflammatory disorders and microbial diseases
06/07/2007WO2007064697A1 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
06/07/2007WO2007064691A1 Treatment of cancer and other diseases
06/07/2007WO2007064664A2 Prostaglandin ep4 agonists for the treatment of gastric conditions
06/07/2007WO2007064658A2 Safe and effective methods of administering therapeutic agents
06/07/2007WO2007064619A1 Pyrimidine derivatives as hiv integrase inhibitors
06/07/2007WO2007064618A1 Methods for the treatment of muscle loss
06/07/2007WO2007064607A2 Formulation and methods for use of morinda citrifolia seed oil
06/07/2007WO2007064595A2 Fluocinolone acetonide drug substance polymorphic interconversion
06/07/2007WO2007064586A1 Methods of treating anxiety disorders
06/07/2007WO2007064582A2 Nitroglycerin therapy for those unable to metabolize nitroglycerin
06/07/2007WO2007064553A2 Thiazole derivatives as cxcr3 receptor modulators
06/07/2007WO2007064543A1 Hyaluronic acid and hyaluronidase in the enhancement of lens regeneration
06/07/2007WO2007064505A1 Confectionary compositions with magnolia bark extract
06/07/2007WO2007064502A1 Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
06/07/2007WO2007064407A1 Transdermal therapeutic system
06/07/2007WO2007064316A1 Bicyclic heterocycles as hiv integrase inhibitors
06/07/2007WO2007064311A1 Micronized mirtazapine
06/07/2007WO2007064304A1 Biocompatible composition and uses thereof
06/07/2007WO2007064274A1 Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
06/07/2007WO2007064273A1 Phenyl urea derivatives
06/07/2007WO2007064272A1 Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
06/07/2007WO2007064244A1 Medicinal agent
06/07/2007WO2007064181A1 Nail care preparations containing terbinafine hydrochloride
06/07/2007WO2007064128A1 Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts
06/07/2007WO2007064045A1 Fused heterocyclic compound
06/07/2007WO2007064010A1 Preventive/therapeutic agent for alzheimer's dementia
06/07/2007WO2007063950A1 Long-wave fluorescent substance for diagnosis or treatment of conformation disease and use thereof
06/07/2007WO2007063946A1 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
06/07/2007WO2007063935A1 Aromatic compound
06/07/2007WO2007063934A1 Alicyclic heterocyclic compound
06/07/2007WO2007063928A1 Novel noncyclic amine carboxamide derivative and salt thereof
06/07/2007WO2007063925A1 2-aminobenzamide derivative
06/07/2007WO2007063868A1 Arylmethylene urea derivative and use thereof
06/07/2007WO2007063866A1 Novel protein and dna encoding the protein
06/07/2007WO2007063839A1 Cyclohexane derivative
06/07/2007WO2007063822A1 Acid addition salt of dihydropyridine derivative
06/07/2007WO2007063821A1 Acid addition salt of optically active dihydropyridine derivative
06/07/2007WO2007063789A1 Novel catechol derivative, pharmaceutical composition containing same, and uses of those
06/07/2007WO2007063648A1 Agent for improving obesity conditions
06/07/2007WO2007063552A1 Stable taste masked formulations of cephalosporins
06/07/2007WO2007063551A1 POLYMORPHS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(l-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-lH-PYRROLE-l-HEPTANOIC ACID MAGNESIUM SALT (2: 1)
06/07/2007WO2007063538A1 Use of a3 adenosine receptor agonist in osteoarthritis treatment
06/07/2007WO2007063418A2 Substituted indole compounds having nos inhibitory activity
06/07/2007WO2007063391A2 Spirocyclic quinazoline derivatives as pde7 inhibitors
06/07/2007WO2007063293A1 Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
06/07/2007WO2007063291A1 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
06/07/2007WO2007063255A1 Composition in the form of a spray containing a vitamin d derivative and an oil phase
06/07/2007WO2007063254A1 Composition in the form of a spray containing a corticoid and an oil phase
06/07/2007WO2007063143A1 Lipid mixture and use thereof for the preparation of a product that is intended for enteral or oral administration
06/07/2007WO2007063124A1 Use of a compound comprising a camptothecin derivative for preparing pharmaceutical formulations useful in the treatment of melanoma
06/07/2007WO2007063123A1 Substituted oxindol-derivatives, medicaments containing said derivatives and use thereof
06/07/2007WO2007063095A1 Use of zinc salts of lipoic acid for treating fat metabolism disorders
06/07/2007WO2007063086A1 Novel nk1 and nk2 antagonists
1 ... 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733 3734 3735 3736 3737 3738 3739 ... 7860